Share ownership GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:29 2026-02-13 EST			5-day change	1st Jan Change
2,165.00 ^GBX	+1.12%		-1.50%	+18.66%

02-13	GSK : Receives a Buy rating from Jefferies	ZD
02-13	Bernstein, Barclays and Deutsche lower Relx	AN

Share class: GSK plc

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	4,315,116,636	4,078,489,304 ( 94.52 %)	169,171,155 ( 3.92 %)	94.52 %

Major shareholders: GSK plc

Name	Equities	%	Valuation
The Vanguard Group, Inc. 2.769 %	112,856,911	2.769 %	2 906 M p
Dodge & Cox 2.438 %	99,377,874	2.438 %	2 559 M p
Schroder Investment Management Ltd. 1.65 %	67,238,966	1.65 %	1 731 M p
Norges Bank Investment Management 1.604 %	65,370,000	1.604 %	1 683 M p
BlackRock Advisors (UK) Ltd. 1.575 %	64,194,517	1.575 %	1 653 M p
Wellington Management Co. LLP 1.548 %	63,106,950	1.548 %	1 625 M p
BlackRock Fund Advisors 1.528 %	62,257,999	1.528 %	1 603 M p
Legal & General Investment Management Ltd. 1.324 %	53,961,870	1.324 %	1 390 M p
SSgA Funds Management, Inc. 1.264 %	51,500,325	1.264 %	1 326 M p
Vanguard Asset Management Ltd. 1.199 %	48,857,000	1.199 %	1 258 M p
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Dodge & Cox 3.362 %	68,517,969	3.362 %	3 536 M p
Fidelity Management & Research Co. LLC 3.246 %	66,143,500	3.246 %	3 413 M p
Fisher Asset Management LLC 1.629 %	33,195,985	1.629 %	1 713 M p
PRIMECAP Management Co. 1.233 %	25,130,160	1.233 %	1 297 M p
JTC Employer Solutions Trustee Ltd. 0.708 %	14,428,009	0.708 %	744 M p
RBC Private Counsel (USA), Inc. 0.5628 %	11,468,469	0.5628 %	592 M p
Acadian Asset Management LLC 0.4399 %	8,964,159	0.4399 %	463 M p
T. Rowe Price International Ltd. 0.3902 %	7,952,012	0.3902 %	410 M p
Goldman Sachs Asset Management LP 0.3552 %	7,237,314	0.3552 %	373 M p
Holocene Advisors, LP 0.3485 %	7,100,420	0.3485 %	366 M p
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	61.52%
Other	3.36%
Individuals	0.34%
State Street Corp.	0.15%
Manulife Financial Corp.	0.09%
SEI Investments Co.	0.04%
Governments	0.03%
ABC arbitrage SA	0.01%
Cullen/Frost Bankers, Inc.	0.01%
Silvercrest Asset Management Group, Inc.	0.01%
Unknown	34.44%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	28.16%
United Kingdom	22.53%
Germany	1.89%
Norway	1.81%
Switzerland	1.65%
Canada	1.42%
France	1.25%
Netherlands	1.17%
Italy	0.73%
Japan	0.71%
Sweden	0.58%
Singapore	0.38%
Denmark	0.35%
Individuals	0.34%
Spain	0.34%
South Korea	0.33%
Australia	0.32%
Luxembourg	0.28%
Hong Kong	0.27%
Ireland	0.26%
Belgium	0.24%
Finland	0.14%
Austria	0.12%
South Africa	0.09%
New Zealand	0.06%
Saudi Arabia	0.05%
Kazakhstan	0.03%
Thailand	0.01%
Liechtenstein	0.01%
Bermuda	0.01%
Puerto Rico	0.01%
Mexico	0.01%
Israel	0.01%

Based on 1000 largest holdings

GSK plc is a global biopharma company. The Companyâ€™s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Employees

68,629

Sector

Pharmaceuticals

Calendar

02-18 - for dividende intermédiaire

More about the company